Xu Jing Su
Contatto Relazioni con gli Investitori presso Taizhou EOC Pharma Co., Ltd.
Profilo
Xu Jing Su currently works at Taizhou EOC Pharma Co., Ltd., as Board Secretary & Legal Director from 2019.
Mr. Su received his graduate degree in 2009 from Soochow University and graduate degree in 2005 from Yanshan University.
Posizioni attive di Xu Jing Su
Società | Posizione | Inizio |
---|---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Contatto Relazioni con gli Investitori | - |
Formazione di Xu Jing Su
Yanshan University | Graduate Degree |
Soochow University | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |
- Borsa valori
- Insiders
- Xu Jing Su